Clinical trial
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment
NCT01694277 is registered in ClinicalTrials.gov with AB Science as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment
- Lead sponsor
- AB Science
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2012
- Completion date
- December 31, 2020
- Enrollment
- 258 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.